BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

Kyowa Kirin Co., Ltd. And Kura Oncology, Inc. Advance Ziftomenib With Japan Phase 2 Trial In NPM1 Mutated AML

Regulatory Filing in Japan Planned Following Clinical Trial Completion – Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura...

April 27, 2026 | News

Leinco Technologies And CellCarta Partner To Advance Proteomics In Immuno Oncology

Leinco Technologies, a leader in antibody and protein development, and CellCarta, a global provider of precision medicine laboratory services, are ple...

April 22, 2026 | News

Akamis Bio Reports Promising Early Efficacy For NG 350A In Rectal Cancer Study

NG-350A combined with chemoradiotherapy demonstrated promising efficacy and a favorable safety profile Composite response rate of 50 percent observed ac...

April 21, 2026 | News

Samsung Bioepis Initiates Phase 1 Clinical Trial for Novel ADC Candidate SBE303 Targeting Nectin 4

Samsung Bioepis Co., Ltd. announced the initiation of a Phase 1 clinical trial for SBE303, its first novel antibody drug conjugate candidate designed...

April 16, 2026 | News

Kazia Therapeutics Expands Oncology Pipeline With SETDB1 Targeted Epigenetic Platform

Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment re...

April 15, 2026 | News

Oricell Therapeutics Raises Over USD 110 Million To Accelerate Global CAR T Innovation

Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, announc...

April 13, 2026 | News

Lumonus And Memorial Sloan Kettering Cancer Center Collaborate To Scale Automated Radiation Therapy Planning

Lumonus, the company behind Lumonus AI, a platform for radiation oncology clinical workflow and automated treatment planning, announced a collaboration wit...

April 09, 2026 | News

IDEAYA Biosciences Advances IDE574 Into Phase 1 As First Patient Enrolled For KAT6 And KAT7 Dual Inhibitor

Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency...

April 07, 2026 | News

Syneron Bio Secures Series B Financing To Advance Macrocyclic Peptide Discovery Platform And Clinical Pipeline

Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on Marc...

April 06, 2026 | News

CellCarta And Pillar Biosciences Partner To Accelerate NGS Tumor Profiling For Biomarker Driven Oncology Trials

CellCarta, a global provider of precision medicine laboratory services for drug development, and Pillar Biosciences, a leader in NGS-based oncology molecul...

April 03, 2026 | News

Abbisko Therapeutics Secures EMA Orphan Drug Status For Irpagratinib In Liver Cancer

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, highly selective, oral...

April 02, 2026 | News

Eisai And Nuvation Bio Advance Taletrectinib With EMA Validation For ROS1 Positive Lung Cancer

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company w...

March 30, 2026 | News

Akeso Advances IO 2.0 Plus ADC 2.0 Strategy With Phase II Trial Clearance In China

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that it has received clearance from the Center for Drug Evaluation (CDE) of China's ...

March 26, 2026 | News

Alphamab Oncology Initiates Phase III Study Of Anbenitamab In HER2 Positive Breast Cancer

Alphamab Oncology announced that the first patient has been dosed in the Phase III clinical study (KN026-007) of HER2 bispecific antibody Anbenitamab (KN02...

March 25, 2026 | News

Stay Connected